Exact Sciences's (EXAS) Outlook

Company Name, Ticker, Competitors, else..

Exact Sciences Corporation (NASDAQ: EXAS)

Sector • Healthcare Industry • Medical Laboratories

Industry • Medical Laboratories

Sector • Healthcare

Exact Sciences Corporation Outlook

On January 13 2025 the Exact Sciences Corporation provided following guidance

Exact Sciences Corporation has released preliminary financial results for the fourth quarter of 2024, offering insight into the company's strong performance. According to their latest projections, the corporation anticipates generating revenue of approximately $713 million for the period that concluded on December 31, 2024.

Based in Madison, Wisconsin, Exact Sciences Corp. (Nasdaq: EXAS) is recognized as a frontrunner in the field of cancer screening and diagnostic testing. The Exact Sciences team achieved remarkable results as we wrapped up 2024, positioning us for continued growth and profitability in the future, stated Kevin Conroy, the chairman and CEO of the company. We are eager to broaden our impact as a foundational platform in the fight against cancer.

These forthcoming figures reflect Exact Sciences' commitment to innovation and excellence in cancer diagnostics, reinforcing its role as a key player in enhancing patient care through early detection and effective treatment options. The impressive revenue projection is indicative of the company's robust operations and strategic initiatives aimed at expanding their market presence and improving health outcomes for patients.,

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.